



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

MESAR ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/002876

FILED: 17 MARCH 2005

U.S. APPLICATION NO: 10 598, 816

35 USC §371 DATE:

FOR: SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-

THIENO(2,3-B) (1,5) BENZODIAZEPINE AND SALTS THEREOF

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicants Reg. No. 30,570

Joséph T. Majka

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (609) 627-8508

Date:

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33684-US-PCT APPLICATION NO. 10/598,816 APPLICANT MESAR ET AL. FILING DATE SEPTEMBER 12, 2006

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	CA	WO 04/000847	12/31/03	Adamed SP. Z O.O.				
	СВ	GB 1533235	11/22/78	Lilly Industries Limited				
-	СС							
	CD							
	CE							
	CF							
	CG							
	СН							
	CI							
	CJ							
	СК							
	CL							
	СМ							
	CN							
	СО							
	СР							
	CQ							
	CR							
	cs							
·	СТ							
	C							
	° C							
	cw							
	сх							
	CY							
EXAMIN	CZ			DATE CONSIDERED	-]			

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 0 9 2007

ATTY. DOCKET NO. 33684-US-PCT APPLICATION NO. 10/598,816 APPLICANT MESAR ET AL. FILING DATE SEPTEMBER 12, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
, ,	AA	2002/0165225	11/7/02	Hamied et, al			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	АН						
	ΑI						
-	AJ						
	AK		*				
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM	EP 0454436	10/30/91	Lilly Industries Ltd.				
	AN	WO 03/101997 ,	12/11/03	Geneva Pharmaceuticals				
	AO	WO 05/070938	8/4/05	Synthon B.V.				
	AP	EP 0733635	9/25/96	Eli Lilly and Company				
	AQ	WO 04/089313	10/21/04	Transform Pharmaceuticals				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	David O. Calligaro et, al.," The Synthesis and Biological Activity of Some Known and Putative Metabolites of the Atypical Antipsychotic Agent Olanzapine", Bioorganic & Medical Chemistry Letters, vol.7, No1
AS	pp.25-30, 1997
АТ	

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.